Heron Therapeutics (HRTX) Set to Post Quarterly Earnings on Tuesday

Heron Therapeutics (NASDAQ:HRTX) is expected to be releasing its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to post earnings of ($0.03) per share and revenue of $37.50 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, November 9, 2026 at 8:30 AM ET.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter. The firm had revenue of $37.67 million for the quarter, compared to analyst estimates of $42.19 million. Heron Therapeutics had a negative net margin of 22.52% and a negative return on equity of 293.02%. On average, analysts expect Heron Therapeutics to post ($0.14) EPS for the current fiscal year and ($0.12) EPS for the next fiscal year.

Heron Therapeutics Trading Down 0.7%

Shares of NASDAQ HRTX opened at $0.30 on Tuesday. The business has a 50 day simple moving average of $0.33 and a 200 day simple moving average of $0.72. Heron Therapeutics has a 52 week low of $0.26 and a 52 week high of $1.57. The stock has a market cap of $57.09 million, a price-to-earnings ratio of -1.58 and a beta of 1.62. The company has a debt-to-equity ratio of 24.35, a quick ratio of 1.51 and a current ratio of 2.49.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on HRTX shares. Zacks Research upgraded shares of Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, August 3rd. Wall Street Zen upgraded shares of Heron Therapeutics to a “sell” rating in a report on Saturday, August 8th. HC Wainwright lowered shares of Heron Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 11th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Heron Therapeutics in a report on Thursday, October 15th. One analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Heron Therapeutics presently has a consensus rating of “Hold” and an average price target of $2.00.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and marketing medicines for acute care and oncology supportive care. Its products are designed to address unmet needs such as postoperative pain and chemotherapy-induced nausea and vomiting.

The company’s portfolio includes ZYNRELEF, an extended-release solution combining bupivacaine and meloxicam for the management of postoperative pain in adults. Heron also markets CINVANTI, an injectable formulation of aprepitant used as part of a combination regimen to help prevent acute and delayed nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy.

Heron’s commercial activities are primarily focused on the United States, where it works with healthcare providers and institutions to support the use of its products in surgical and oncology settings.